[go: up one dir, main page]

AU2003288263A1 - Use of substituted acrylolyl distamycin derivatives in combination with demethylating agents, in the treatment of cancer - Google Patents

Use of substituted acrylolyl distamycin derivatives in combination with demethylating agents, in the treatment of cancer

Info

Publication number
AU2003288263A1
AU2003288263A1 AU2003288263A AU2003288263A AU2003288263A1 AU 2003288263 A1 AU2003288263 A1 AU 2003288263A1 AU 2003288263 A AU2003288263 A AU 2003288263A AU 2003288263 A AU2003288263 A AU 2003288263A AU 2003288263 A1 AU2003288263 A1 AU 2003288263A1
Authority
AU
Australia
Prior art keywords
acrylolyl
cancer
substituted
treatment
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003288263A
Inventor
Massimo Broggini
Camilla Fowst
Maria Cristina Geroni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Pharmacia Italia SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia SpA filed Critical Pharmacia Italia SpA
Publication of AU2003288263A1 publication Critical patent/AU2003288263A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003288263A 2002-10-16 2003-10-07 Use of substituted acrylolyl distamycin derivatives in combination with demethylating agents, in the treatment of cancer Abandoned AU2003288263A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02079294 2002-10-16
EP02079294.1 2002-10-16
PCT/EP2003/050700 WO2004035045A1 (en) 2002-10-16 2003-10-07 Use of substituted acrylolyl distamycin derivatives in combination with demethylating agents, in the treatment of cancer

Publications (1)

Publication Number Publication Date
AU2003288263A1 true AU2003288263A1 (en) 2004-05-04

Family

ID=32103944

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003288263A Abandoned AU2003288263A1 (en) 2002-10-16 2003-10-07 Use of substituted acrylolyl distamycin derivatives in combination with demethylating agents, in the treatment of cancer

Country Status (2)

Country Link
AU (1) AU2003288263A1 (en)
WO (1) WO2004035045A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007075077A1 (en) * 2005-11-16 2007-07-05 Universidad Nacional Autonoma De Mexico Use of transcriptome-modifying agents and chemotherapy or radiotherapy against cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576612B1 (en) * 2000-10-02 2003-06-10 Pharmacia Italia S.P.A. Antitumor therapy comprising distamycin derivatives

Also Published As

Publication number Publication date
WO2004035045A1 (en) 2004-04-29

Similar Documents

Publication Publication Date Title
IL174994A0 (en) Pyrimidin - 4 - yl - 3, 4 - thione compounds and their use in therapy
AU2003209594A1 (en) Quinazoline compounds useful in therapy
PL370029A1 (en) 2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer
AU2002340999A1 (en) Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use
AU2003254038A1 (en) Glyconjugates comprising carbohydrate epitopes, methods for theirsynthesis, and their use for the treatment or prophylaxis of cancer
AU2003289641A1 (en) The novel coumarin-amide derivatives and its preparation, said drug composition and its use
EP1578782A3 (en) Combination therapy with co-stimulatory factors
IL178402A0 (en) 1-amino-phthalazine derivatives, the preparation and the therapeutic use thereof
AU2003212634A1 (en) Compounds useful in the treatment of cancer
AU2003303388A1 (en) Triptolide derivatives and their use
AU2003255645A1 (en) Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof
ZA200703876B (en) 2-amido -4-phenylthiazole derivatives, the preparation and therapeutic use thereof
AU2003269018A1 (en) Acylaminothiazole derivatives, preparation and therapeutic use thereof
AU2002347747A1 (en) Retinol derivatives, their use in the treatment of cancer and for potentiating the efficacy of other cytotoxic agents
AU2003292381A1 (en) Naphthyridine derivatives and their use as fungicides
IL178261A0 (en) Use of 5,10-methylene tetrahydrofolate for the treatment of cancer
IL180867A0 (en) Pyrrole derivatives, their preparation and their therapeutic use
AU2003245794A1 (en) Glycosaminoglycan-dnase combination therapy
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
AU2003260566A1 (en) Phenyl-furan or phenyl-thiophene derivatives, their preparation and their use as medicine
IL152388A0 (en) Use of substituted acryloyl distamycin derivatives in the treatment of tumors associated with high levels of glutathione
PL375309A1 (en) Acyloxypyrrolidine derivatives, preparation and therapeutic use thereof
AU2003288263A1 (en) Use of substituted acrylolyl distamycin derivatives in combination with demethylating agents, in the treatment of cancer
AU2003900495A0 (en) Aroylhydrazone derivatives and therapeutic uses thereof
AU2003231803A1 (en) Treatment of cancer with mefloquire

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase